Brainose Technologies
Nasal Delivery of Cannabis-derived Therapeutics
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
Brainose Technologies | 03/07/2022 | NeuroPharmacology | NeuroBioTechnology | Biotechnology & Biopharmaceutical | Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis) | Biochemical: pharmacological drugs (Developing drugs) | 01/01/2017 | "1-10" |
Brainose Technologies has developed a nose-to-brain delivery system for cannabis-derived therapeutics for the treatment of central nervous system (CNS) indications. Brainose is currently developing a pharmaceutical-grade cannabinoid-based therapy with a focus on pain management for FDA and CE approval in the U.S. and Europe.
The company’s mission is to provide the huge population that benefits from cannabis-derived therapeutics with accessibility to these medications in a simple, safe, efficient, and friendly manner. Its products are designed to ensure precise and reproducible dose delivery.
Brainose was founded as a collaboration between Cann10, an accelerator focused on medical cannabis, and Nextar Chempharma Solutions, a veteran pharmaceutical company. Brainose has partnered with SipNose to further progress on its drug delivery platform.